Axe Compute Inc

Research Axe Compute Inc (AGPU) on Bullrun: market cap USD 117.83M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 117.83M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 125.28K-USD 233.10M-USD 9.88M42.0%-129.17USD 10.79MUSD 1.67MUSD 47.72M
FY2024USD 84.81K-USD 12.66M-USD 10.11M7.7%-16.58USD 611.82KUSD 2.11M-USD 202.61K
FY2023USD 492.60K-USD 13.98M-USD 13.20M60.4%n/aUSD 8.36MUSD 0USD 8.27M
FY2022USD 1.51M-USD 25.74M-USD 12.79M66.4%n/aUSD 22.07MUSD 0USD 21.77M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 117.83Mn/an/an/a
20252025-12-31USD 24.26Mn/an/an/a
20242024-12-31USD 5.47Mn/an/an/a
20232023-12-29USD 13.37Mn/an/an/a
20222022-12-30USD 24.18Mn/an/an/a
20212021-12-31USD 62.46Mn/an/an/a

About Axe Compute Inc

Axe Compute Inc. provides access to graphics processing unit and digital asset treasury strategy. The company operates through two segments: Compute Services and Treasury Management; and Drug Discovery Services. The Compute Services and Treasury Management segment provides access to graphics processing unit compute capacity and digital asset treasury strategy focused on Aethir token.

Related stock research

Other Technology stocks

Frequently asked questions

What is Axe Compute Inc's market cap?

Axe Compute Inc's market capitalization is USD 117.83M.

What does Axe Compute Inc do?

Axe Compute Inc. provides access to graphics processing unit and digital asset treasury strategy. The company operates through two segments: Compute Services and Treasury Management; and Drug Discovery Services. The Compute Services and Treasury Management segment provides access to graphics processing unit compute capacity and digital asset treasury strategy focused on Aethir token. The Drug Discovery Services segment engages in the application of AI using its proprietary biobank of 150,000+ tumor samples, as well as creation of proprietary 3D culture models used in drug development.